Measuring the societal burden of cancer: The cost of lost productivity due to premature cancer‐related mortality in Europe

Abstract

Every cancer-related death in someone of working age represents an economic loss to society. To inform priorities for cancer control, we estimated costs of lost productivity due to premature cancer-related mortality across Europe, for all cancers and by site, gender, region and country. Cancer deaths in 2008 were obtained from GLOBOCAN for 30 European countries across four regions. Costs were valued using the human capital approach. Years of productive life lost (YPLL) were computed by multiplying deaths between 15 and 64 years by working-life expectancy, then by country-, age-and gender-specific annual wages, corrected for workforce participation and unemployment. Lost productivity costs due to premature cancer-related mortality in Europe in 2008 were e75 billion. Male costs (e49 billion) were almost twice female costs (e26 billion). The most costly sites were lung (e17 billion; 23% of total costs), breast (e7 billion; 9%) and colorectum (e6 billion; 8%). Stomach cancer (in Southern and Central-Eastern Europe) and pancreatic cancer (in Northern and Western Europe) were also among the most costly sites. The average lost productivity cost per cancer death was e219,241. Melanoma had the highest cost per death (e312,798), followed by Hodgkin disease (e306,628) and brain and CNS cancer (e288,850). Premature mortality costs were 0.58% of 2008 European gross domestic product, highest in Central-Eastern Europe (0.81%) and lowest in Northern Europe (0.51%). Premature cancer-related mortality costs in Europe are significant. These results provide a novel perspective on the societal cancer burden and may be used to inform priority setting for cancer control.

Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study

“…Lung cancer is the most-common cause of loss of productivity and life, as it leads to premature cancer-related mortality (1)(2)(3). Furthermore, most cases of lung cancer are detected at an old age, resulting in poor prognosis (4).…”

Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064)

“…Thus, it is one of the three most common causes of cancer deaths in adults of both sexes [1,2]. Furthermore, colorectal cancer has a tremendous economic impact accounting for approximately € 6 billion costs due to lost productivity in Europe 2008, because of cancer-related premature mortality [3].…”

Can protein science solve the unmet needs in pancreatic cancer diagnosis and therapy?

“…The health-care costs associated with pancreatic cancer has been calculated to be approximately 86-93 million euros annually in Sweden [5]. Furthermore, pancreatic cancer is reported to be the fifth most costly cancer site at an expense of 3.9 billion euros annually in Europe [6]. Screening programs for pancreatic cancer do exist in patients with hereditary risk factors and known genetic syndromes associated with pancreatic cancer, using conventional imaging techniques such as magnetic resonance imaging and endoscopic ultrasound.…”